Why it Matters
This marks a significant expansion of Acesso Biologics‘ lobbying presence in Washington. The regenerative medicine company is doubling down on advocacy efforts by adding the McManus Group to its roster. This brings their 2025 lobbying spend to $250,000 across two firms.
By the Numbers
Current Quarter: Acesso paid McManus Group $50,000 for Q2 2025 representation.
Historical Spending: The company spent $170,000 with Michael Best Strategies LLC across six filings in 2024-2025.
Lobbying Team: John E. McManus and Alex Whalen are handling the account.
McManus’ Background: Former House Ways and Means Health Subcommittee Staff Director (2004-2005). Previous clients include Amgen Inc., Genentech Inc., and PhRMA.
Broader Context
Congress is actively considering multiple bills affecting regenerative medicine companies. The House Energy and Commerce Committee recently advanced legislation strengthening safety standards for human cell and tissue products. Several lawmakers have shown increased interest through facility visits and communications about industry reforms.
The Agenda
Acesso is lobbying on Medicare coverage and reimbursement for Human Cell & Tissue products. Their focus remains on Local Coverage Determination L39764, which covers skin substitute grafts for diabetic foot ulcers and venous leg ulcers. The company has consistently targeted this specific Medicare policy across both lobbying firms.
Competitive Landscape
Acesso faces significant competition in Washington lobbying efforts. Multiple wound care companies are targeting the same Medicare coverage issues, including Organogenesis Inc., BioWound Solutions LLC, VIVEX Biologics Inc., ConvaTec Advanced Tissue Technologies, and Integra LifeSciences Corp..
Between The Lines
Key legislation is moving through Congress that could reshape the industry. Senator Bill Cassidy’s S.2561 – Skin Substitute Access and Payment Reform Act of 2025 would standardize Medicare payments for skin substitutes. The bipartisan H.R.340 – The HCT/P Modernization Act of 2025 aims to streamline FDA oversight. Representatives have been visiting facilities and communicating about industry reforms.
The Bottom Line
Acesso’s dual-firm strategy reflects the competitive Medicare reimbursement landscape. With multiple relevant bills in play and sustained industry lobbying, the company is positioning itself for potential policy changes that could significantly impact wound care coverage.